Evidence map›Paper›PMID 33283986›Full record

ArticleJournal of the International AIDS Society2020

Pathways for reduction of HIV-related stigma: a model derived from longitudinal qualitative research in Kenya and Uganda.

Carol S Camlin, Edwin D Charlebois, Monica Getahun, Cecilia Akatukwasa, Frederick Atwine, Harriet Itiakorit, Robert Bakanoma, Irene Maeri, Lawrence Owino, Anjeline Onyango and 10 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
NCT04772469 nacompletednot on this mapstarted 2021, after this paper: background citation

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men

TypeinterventionalSponsorUniversity of California, San FranciscoRan2021 to 2023Enrolled934ConditionsHuman Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, HIV Infections, Sexually Transmitted Diseases, ViralArmsProvision of multiple self-tests, Small monetary incentives, Use of SMS/text reminders to motivate adherence to ART or PrEP
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Carol S CamlinDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5615-1164
Edwin D CharleboisDepartment of Medicine, Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, USA.
Monica GetahunDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Cecilia AkatukwasaInfectious Diseases Research Collaboration, Kampala, Uganda.
Frederick AtwineInfectious Diseases Research Collaboration, Kampala, Uganda.
Harriet ItiakoritInfectious Diseases Research Collaboration, Kampala, Uganda.
Robert BakanomaInfectious Diseases Research Collaboration, Kampala, Uganda.
Irene MaeriKenya Medical Research Institute, Nairobi, Kenya.
Lawrence OwinoKenya Medical Research Institute, Nairobi, Kenya.
Anjeline OnyangoKenya Medical Research Institute, Nairobi, Kenya.
Gabriel ChamieDivision of HIV, Department of Medicine, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5860-8081
Tamara D ClarkDivision of HIV, Department of Medicine, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA, USA.
Craig R CohenDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Dalsone KwarisiimaInfectious Diseases Research Collaboration, Kampala, Uganda.
Jane KabamiInfectious Diseases Research Collaboration, Kampala, Uganda.
Norton SangKenya Medical Research Institute, Nairobi, Kenya.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Elizabeth A BukusiKenya Medical Research Institute, Nairobi, Kenya.
Maya L PetersenDivisions of Biostatistics and Epidemiology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Diane V HavlirDivision of HIV, Department of Medicine, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0761-3136
Infectious Diseases Research Collaboration · UGUniversity of California, San Francisco · USKenya Medical Research Institute · KEUniversity of California, Berkeley · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)U01AI099959 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2016
$39.7M
Bill & Melinda Gates FoundationNIAID NIH HHS U01 AI099959NIAID NIH HHS U01AI099959NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1AI068636PEPFAR
6 · The paper itself

Abstract

introductionThe rollout of antiretroviral therapy (ART) has been associated with reductions in HIV-related stigma, but pathways through which this reduction occurs are poorly understood. In the newer context of universal test and treat (UTT) interventions, where rapid diffusion of ART uptake takes place, there is an opportunity to understand the processes through which HIV-related stigma can decline, and how UTT strategies may precipitate more rapid and widespread changes in stigma. This qualitative study sought to evaluate how a UTT intervention influenced changes in beliefs, attitudes and behaviours related to HIV.

methodsLongitudinal qualitative in-depth semi-structured interview data were collected within a community-cluster randomized UTT trial, the Sustainable East Africa Research in Community Health (SEARCH) study, annually over three rounds (2014 to 2016) from two cohorts of adults (n = 32 community leaders, and n = 112 community members) in eight rural communities in Uganda and Kenya. Data were inductively analysed to develop new theory for understanding the pathways of stigma decline.

resultsWe present an emergent theoretical model of pathways through which HIV-related stigma may decline: internalized stigma may be reduced by two processes accelerated through the uptake and successful usage of ART: first, a reduced fear of dying and increased optimism for prolonged and healthy years of life; second, a restoration of perceived social value and fulfilment of subjective role expectations via restored physical strength and productivity. Anticipated stigma may be reduced in response to widespread engagement in HIV testing, leading to an increasing number of HIV status disclosures in a community, "normalizing" disclosure and reducing fears. Improvements in the perceived quality of HIV care lead to people living with HIV (PLHIV) seeking care in nearby facilities, seeing other known community members living with HIV, reducing isolation and facilitating opportunities for social support and "solidarity." Finally, enacted stigma may be reduced in response to the community viewing the healthy bodies of PLHIV successfully engaged in treatment, which lessens the fears that trigger enacted stigma; it becomes no longer socially normative to stigmatize PLHIV. This process may be reinforced through public health messaging and anti-discrimination laws.

conclusionsDeclines in HIV-related stigma appear to underway and explained by social processes accelerated by UTT efforts. Widespread implementation of UTT shows promise for reducing multiple dimensions of stigma, which is critical for improving health outcomes among PLHIV.

Indexed as

Qualitative ResearchSocial StigmaAdultFemaleHIV InfectionsHumansKenyaMalePatient Acceptance of Health CarePublic HealthSocial SupportUgandacommunityHIV-related stigmaHIV testingHIV treatmentsub-Saharan AfricaUniversal Testing and Treatment

Identifiers

PMID33283986
PMCPMC7720278
OpenAlexW3111588634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.